Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.
- Published In:
- TouchREVIEWS in endocrinology, 20(2), 62-71 (2024)
- Authors:
- Qamar, Sulmaaz, Mallik, Ritwika, Makaronidis, Janine
- Database ID:
- RPEP-09098
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09098APA
Qamar, Sulmaaz; Mallik, Ritwika; Makaronidis, Janine. (2024). Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.. TouchREVIEWS in endocrinology, 20(2), 62-71. https://doi.org/10.17925/EE.2024.20.2.9
MLA
Qamar, Sulmaaz, et al. "Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.." TouchREVIEWS in endocrinology, 2024. https://doi.org/10.17925/EE.2024.20.2.9
RethinkPeptides
RethinkPeptides Research Database. "Setmelanotide: A Melanocortin-4 Receptor Agonist for the Tre..." RPEP-09098. Retrieved from https://rethinkpeptides.com/research/qamar-2024-setmelanotide-a-melanocortin4-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.